Search: onr:"swepub:oai:DiVA.org:uu-144513" >
Ticagrelor vs. clop...
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes : a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial
-
- James, Stefan (author)
- Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)
-
Angiolillo, Dominick J. (author)
-
Cornel, Jan H. (author)
-
show more...
-
- Erlinge, David (author)
- Lund University,Lunds universitet,Kardiologi,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Cardiology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine
-
Husted, Steen (author)
-
Kontny, Frederic (author)
-
Maya, Juan (author)
-
Nicolau, Jose C. (author)
-
Spinar, Jindrich (author)
-
Storey, Robert F. (author)
-
Stevens, Susanna R. (author)
-
- Wallentin, Lars (author)
- Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)
-
show less...
-
(creator_code:org_t)
- 2010-08-29
- 2010
- English.
-
In: European Heart Journal. - : Oxford University Press (OUP). - 0195-668X .- 1522-9645. ; 31:24, s. 3006-3016
- Related links:
-
https://academic.oup...
-
show more...
-
http://dx.doi.org/10...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://lup.lub.lu.s...
-
show less...
Abstract
Subject headings
Close
- Patients with diabetes mellitus (DM) have high platelet reactivity and are at increased risk of ischaemic events and bleeding post-acute coronary syndromes (ACS). In the PLATelet inhibition and patient Outcomes (PLATO) trial, ticagrelor reduced the primary composite endpoint of cardiovascular death, myocardial infarction, or stroke, but with similar rates of major bleeding compared with clopidogrel. We aimed to investigate the outcome with ticagrelor vs. clopidogrel in patients with DM or poor glycaemic control. We analysed patients with pre-existing DM (n = 4662), including 1036 patients on insulin, those without DM (n = 13 951), and subgroups based on admission levels of haemoglobin A1c (HbA1c; n = 15 150). In patients with DM, the reduction in the primary composite endpoint (HR: 0.88, 95% CI: 0.76-1.03), all-cause mortality (HR: 0.82, 95% CI: 0.66-1.01), and stent thrombosis (HR: 0.65, 95% CI: 0.36-1.17) with no increase in major bleeding (HR: 0.95, 95% CI: 0.81-1.12) with ticagrelor was consistent with the overall cohort and without significant diabetes status-by-treatment interactions. There was no heterogeneity between patients with or without ongoing insulin treatment. Ticagrelor reduced the primary endpoint, all-cause mortality, and stent thrombosis in patients with HbA1c above the median (HR: 0.80, 95% CI: 0.70-0.91; HR: 0.78, 95% CI: 0.65-0.93; and HR: 0.62, 95% CI: 0.39-1.00, respectively) with similar bleeding rates (HR: 0.98, 95% CI: 0.86-1.12). Ticagrelor, when compared with clopidogrel, reduced ischaemic events in ACS patients irrespective of diabetic status and glycaemic control, without an increase in major bleeding events.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Keyword
- Acute coronary syndromes
- Diabetes
- Ticagrelor
- Clopidogrel
- Mortality
- Myocardial infarction
- MEDICINE
- MEDICIN
- Acute coronary syndromes
- Diabetes
- Ticagrelor
- Clopidogrel
- Mortality
- Myocardial infarction
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
James, Stefan
-
Angiolillo, Domi ...
-
Cornel, Jan H.
-
Erlinge, David
-
Husted, Steen
-
Kontny, Frederic
-
show more...
-
Maya, Juan
-
Nicolau, Jose C.
-
Spinar, Jindrich
-
Storey, Robert F ...
-
Stevens, Susanna ...
-
Wallentin, Lars
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cardiac and Card ...
- Articles in the publication
-
European Heart J ...
- By the university
-
Uppsala University
-
Lund University